List of Excipients in Branded Drug ERLOTINIB HYDROCHLORIDE

Generic Drugs Containing ERLOTINIB HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	erlotinib hydrochloride	0378-7131	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	erlotinib hydrochloride	0378-7131	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	erlotinib hydrochloride	0378-7131	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ERLOTINIB HYDROCHLORIDE?

# Of NDCs	Excipient
5	CELLULOSE, MICROCRYSTALLINE
4	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSE

Last updated: August 12, 2026

Erlotinib hydrochloride is a mature, genericized small-molecule oncology product. The active ingredient has limited remaining composition-of-matter exclusivity value, while commercial opportunities center on bioavailability control, excipient compatibility, reduced food and acid-reducer sensitivity, lower tablet burden, and differentiated oral-solid manufacturing. The strongest near-term opportunity is a robust, low-cost immediate-release tablet or capsule with tighter dissolution performance and a documented control strategy for pH-dependent solubility.

Erlotinib Hydrochloride Excipient Strategy and Commercial Opportunities

What is the commercial status of erlotinib hydrochloride?

Erlotinib hydrochloride is the hydrochloride salt of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. The originator product, Tarceva, was developed by OSI Pharmaceuticals and Genentech, with Roche later assuming commercial responsibility in several markets. The FDA approved Tarceva in 2004 for locally advanced or metastatic non-small-cell lung cancer and later expanded its use to pancreatic cancer in combination with gemcitabine.[1]

Erlotinib is now available from multiple generic manufacturers. The market is therefore driven less by basic active pharmaceutical ingredient exclusivity and more by:

• Manufacturing cost
• Assured API supply
• Tablet compression and coating performance
• Dissolution reproducibility
• Stability in humid conditions
• Supply reliability for oncology channels
• Formulation differentiation
• Geographic registration and tender access

Erlotinib is a small molecule, not a biologic. Biosimilar competition does not apply. The relevant competitors are generic tablets, authorized generics, contract manufacturers, and potential reformulations.

Key product characteristics

Attribute	Erlotinib hydrochloride
Therapeutic class	EGFR tyrosine kinase inhibitor
Dosage form	Immediate-release oral tablet
Common strengths	25 mg, 100 mg, 150 mg
Originator brand	Tarceva
Regulatory category	Small-molecule prescription drug
Primary formulation issue	Poor and pH-dependent aqueous solubility
Main clinical interaction	Reduced exposure with gastric acid suppression
Biosimilar exposure	None
Generic pathway	Abbreviated New Drug Application, subject to FDA requirements
Commercial maturity	Mature generic market

What excipient properties are most important for erlotinib hydrochloride?

The central formulation issue is pH-dependent solubility. Erlotinib is a weakly basic quinazoline compound. Its hydrochloride salt improves handling and initial dissolution, but the molecule remains sensitive to gastric pH. Acid-reducing agents can reduce systemic exposure, creating a formulation and labeling constraint.[2]

A suitable excipient system should support:

1. Rapid wetting and dispersion.
2. Consistent dissolution across relevant pH conditions.
3. Low moisture uptake.
4. Chemical stability of the hydrochloride salt.
5. Acceptable tablet hardness without delayed disintegration.
6. Scalable direct compression or wet-granulation processing.
7. Low risk of adsorption or chemical interaction with the API.
8. A cost profile suitable for generic oncology pricing.

The formulation target is not simply higher dissolution in acidic medium. A commercially useful formulation should maintain predictable release as the medium shifts toward less acidic intestinal conditions.

What excipients are used in Tarceva tablets?

The Tarceva label identifies a conventional immediate-release tablet platform. The core includes lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate. The film coating contains conventional polymeric and opacifying materials, including hypromellose, hydroxypropyl cellulose, titanium dioxide, and polyethylene glycol or macrogol-type plasticizer materials, depending on market presentation.[1]

Originator-style excipient functions

Excipient	Primary function	Erlotinib relevance
Lactose monohydrate	Diluent	Supports tablet mass and compression
Microcrystalline cellulose	Diluent and dry binder	Improves compactibility
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup
Sodium lauryl sulfate	Wetting agent	Can improve wetting of hydrophobic API
Magnesium stearate	Lubricant	Controls ejection force
Hypromellose	Film former	Protects tablet and improves appearance
Hydroxypropyl cellulose	Coating polymer or binder	Supports coating and film integrity
Titanium dioxide	Opacifier and colorant	Provides coating opacity
Polyethylene glycol or macrogol	Plasticizer	Reduces coating brittleness

This excipient set is commercially practical, but it does not eliminate the underlying pH-dependent exposure issue. A generic developer can use the same functional classes while changing grades, concentrations, granulation method, or coating composition.

Which excipient strategies can improve erlotinib performance?

Surfactant-assisted wetting

Sodium lauryl sulfate and other surfactants can improve wetting and initial dissolution of hydrophobic erlotinib particles. The concentration must be controlled because excessive surfactant can affect tablet strength, gastrointestinal tolerability, powder flow, and dissolution behavior.

Potential alternatives include:

• Sodium lauryl sulfate
• Poloxamers
• Polyoxyethylene-based surfactants
• Sodium docusate, subject to compatibility and regulatory review

The commercial value is highest when the surfactant enables a lower-cost manufacturing process without requiring a complex amorphous dispersion.

Superdisintegrant optimization

Crospovidone, croscarmellose sodium, and sodium starch glycolate can be evaluated as alternatives or complements to the originator approach. The key variables are:

• Intra- versus extra-granular placement
• Disintegrant concentration
• Tablet porosity
• Compression force
• Lubrication time
• Granule size distribution

Crospovidone may support rapid liquid uptake, while croscarmellose sodium can provide strong swelling and wicking. Sodium starch glycolate is commercially familiar but can be sensitive to over-lubrication and high compression force.

Amorphous solid dispersion

An amorphous solid dispersion can increase apparent solubility and improve dissolution under less acidic conditions. Candidate polymers may include:

• Hypromellose
• Hypromellose acetate succinate
• Hydroxypropyl cellulose
• Povidone
• Copovidone
• Soluplus-type graft copolymers

This approach carries higher development and manufacturing costs. The principal risks are recrystallization, moisture-induced phase change, residual solvent control, and stability over the proposed shelf life.

For a mature generic drug, an amorphous dispersion is commercially justified only when it creates a meaningful performance advantage, enables a new dosage form, or supports a differentiated regulatory strategy.

Lipid or self-emulsifying systems

Lipid-based systems may increase apparent solubilization, but they are less naturally aligned with a conventional low-cost tablet. They may be useful for:

• Liquid-filled capsules
• Pediatric oral liquids
• Poorly swallowing populations
• Formulations intended to reduce variability after administration

The main risks are capsule compatibility, oxidation, fill-process complexity, and the need to demonstrate robust content uniformity.

pH-modifying excipients

Organic acids or buffering agents can create a favorable microenvironment around the dissolving drug. Candidate materials may include citric acid, fumaric acid, succinic acid, or other pharmaceutically acceptable acids.

This strategy requires careful evaluation because a local acidic microenvironment may improve dissolution in vitro without fully overcoming in vivo gastric pH variability. It can also affect hygroscopicity, chemical stability, tablet hardness, and taste.

What formulation is most commercially attractive?

For most generic manufacturers, the best risk-adjusted design is a conventional immediate-release tablet with an optimized excipient system rather than a high-complexity reformulation.

Preferred first-line formulation concept

A practical development platform would include:

• Erlotinib hydrochloride API with controlled particle-size distribution
• Microcrystalline cellulose or an equivalent compressible diluent
• A superdisintegrant optimized for rapid breakup
• A low level of surfactant to improve wetting
• A low-moisture binder system
• Magnesium stearate with controlled lubrication time
• A moisture-protective film coat

The development program should compare direct compression, dry granulation, and wet granulation. Direct compression offers the lowest process cost but may be limited by API flow, segregation, and dose uniformity. Dry granulation can improve flow without introducing water. Wet granulation may improve uniformity but introduces a potential stability burden.

What formulation patents may protect erlotinib products?

Erlotinib formulation protection may arise from several claim types:

• Specific excipient combinations
• Amorphous erlotinib compositions
• Solid dispersions
• Particle-size distributions
• Salt or polymorph forms
• Stabilized compositions
• Modified-release dosage forms
• Oral liquids or dispersible tablets
• Methods of improving dissolution or exposure
• Manufacturing processes that produce a defined solid state

The commercial value of these patents depends on claim breadth and enforceability. A formulation patent covering a broad combination of common excipients may face validity and obviousness challenges. A patent tied to a defined solid form, dissolution profile, manufacturing condition, or stability result can create a stronger technical position.

A generic manufacturer should separate three questions:

1. Does the formulation infringe a live claim?
2. Is the claim valid in view of prior art?
3. Does the product require a Paragraph IV certification or can it use a different regulatory pathway?

A formulation that uses the same API, strength, route, and dosage form may still avoid infringement if it does not practice the claimed excipient combination or process.

What is the Orange Book status of erlotinib?

Tarceva was an FDA-approved small-molecule product with Orange Book-listed patents and exclusivity during its originator period. The principal erlotinib composition-of-matter protection and associated regulatory exclusivity have expired, and generic erlotinib products are approved in the United States.[3]

The relevant current commercial issue is not basic Orange Book exclusivity. It is whether any live, product-specific patent or regulatory restriction affects a proposed generic formulation, method-of-use certification, or labeling strategy.

Paragraph IV challenge risk

Paragraph IV litigation risk is materially lower for a mature product than during the first generic-entry cycle, but it is not zero. Potential disputes can still involve:

• Later-issued formulation patents
• Method-of-use patents
• Pediatric or dosing claims
• Solid-state or manufacturing patents
• Patent listing disputes
• ANDA product descriptions
• Skinny-label strategies

A manufacturer considering a new erlotinib product should review the current FDA Orange Book, the complete patent listing history, and federal litigation databases before filing. Patent status changes over time and should not be inferred solely from the original Tarceva patent portfolio.

When did erlotinib lose exclusivity?

Erlotinib lost the commercial protection associated with its original product patents and regulatory exclusivity in the United States before the present generic-market period. FDA-approved generic erlotinib products confirm that the core product can be commercialized through the ANDA pathway.[3]

The practical exclusivity timeline is:

Period	Commercial position
2004	FDA approval of Tarceva
2004 onward	Originator-led market with regulatory and patent protection
Post-expiration period	Generic entry and price competition
Current market	Mature generic product with reformulation and supply-chain opportunities

The exact launch date of each generic, first-filer status, and any 180-day exclusivity period must be confirmed from FDA approval records for the relevant strength and applicant.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue erlotinib through performance claims rather than drug-specific exclusivity. The most credible opportunities are:

High-value excipient opportunities

Opportunity	Commercial rationale	Development burden
Direct-compression platform	Lowers manufacturing cost	Low to moderate
Co-processed filler-disintegrant	Improves flow and compression	Moderate
Surfactant premix	Improves wetting and batch consistency	Moderate
Moisture-barrier coating	Supports stability and shelf life	Low
Amorphous dispersion polymer	Improves apparent solubility	High
Pediatric taste-masking system	Expands administration options	High
Liquid or dispersible platform	Addresses swallowing limitations	Moderate to high
Continuous-manufacturing excipient system	Improves process control	High

The largest addressable opportunity is likely a robust tablet platform that reduces batch failures and stabilizes dissolution across API lots. A supplier should generate comparative data against commonly used grades rather than rely on generic claims of improved solubility.

How can excipient suppliers support regulatory approval?

An excipient supplier can strengthen a generic development program by providing:

• Type II Drug Master File support where appropriate
• Compendial compliance data
• Residual solvent and elemental impurity data
• Nitrosamine risk assessment
• Peroxide and aldehyde impurity data
• Microbiological specifications
• Extractables and leachables information for packaging interactions
• Stability data under ICH conditions
• Lot-to-lot particle-size and moisture controls
• Compatibility studies with erlotinib hydrochloride

The data package should address the drug product, not only the excipient. Erlotinib development should include compatibility testing under heat, humidity, light, and accelerated storage conditions.

What manufacturing barriers affect erlotinib formulation development?

The principal manufacturing barriers are manageable but commercially relevant.

API particle engineering

Particle-size variation can change flow, blend uniformity, dissolution, and tablet compression. Milling can also increase surface area and may affect moisture uptake or electrostatic behavior.

Lubrication sensitivity

Over-lubrication with magnesium stearate can reduce tablet tensile strength and slow wetting. The risk increases when hydrophobic API particles are already difficult to disperse.

Moisture and solid-state control

A formulation using amorphous material or hygroscopic excipients may require tighter humidity control, moisture-resistant packaging, and enhanced stability testing.

Dissolution method sensitivity

Erlotinib dissolution results can vary with:

• Medium pH
• Surfactant concentration
• Apparatus type
• Agitation rate
• Sink conditions
• Sampling time
• API particle size

A generic product should have a discriminatory, physiologically relevant dissolution method and a clear link between formulation variables and clinical performance.

How does erlotinib compare with competing EGFR inhibitors?

Erlotinib competes clinically with other EGFR-targeted agents, including gefitinib, afatinib, osimertinib, and locally marketed generic EGFR inhibitors. Its main commercial disadvantage is that newer agents have captured substantial clinical preference in settings involving resistant disease or central nervous system activity.

Its commercial advantages are:

• Mature API supply
• Established tablet manufacturing
• Low-cost generic positioning
• Familiar clinical use
• Broad availability in emerging markets
• Potential use where newer agents are inaccessible or unaffordable

The commercial opportunity is therefore strongest in cost-sensitive markets, institutional tenders, oncology access programs, and territories where later-generation EGFR inhibitors remain expensive.

What revenue exposure remains for erlotinib?

Revenue exposure is concentrated in generic volume rather than premium pricing. The main variables are:

• Number of approved suppliers
• National tender pricing
• Availability of 25 mg, 100 mg, and 150 mg strengths
• API cost and supply reliability
• Reimbursement status
• Local registration requirements
• Physician preference for newer EGFR inhibitors
• Demand in EGFR-mutated non-small-cell lung cancer

A differentiated excipient formulation could support a modest price premium only if it demonstrates a measurable benefit, such as improved stability, lower tablet burden, improved dissolution consistency, or a new administration option. An excipient change alone is unlikely to sustain a large premium in a mature generic market.

What generic launch scenarios exist for erlotinib?

Lowest-risk scenario: conventional tablet

The manufacturer uses a conventional immediate-release composition with optimized particle size, wetting, disintegration, and coating. This route has the lowest technical and regulatory risk.

Differentiated tablet scenario

The manufacturer uses a proprietary co-processed excipient system or dissolution-enhancing platform. The opportunity is greater, but comparative analytical and stability data must justify the formulation.

New dosage-form scenario

The manufacturer develops a dispersible tablet, oral suspension, or capsule. This may address patients with swallowing difficulty, but it introduces taste, dose-uniformity, stability, and labeling issues.

Advanced formulation scenario

The manufacturer develops an amorphous dispersion or lipid-based system. This has the greatest formulation differentiation but is difficult to justify unless the product provides a meaningful clinical or commercial advantage.

How strong is the erlotinib patent estate?

The original erlotinib patent estate is commercially weak today because the core product is genericized. Any remaining strength would come from narrow, later-issued claims directed to formulation, manufacturing, solid state, or method of use.

A practical strength assessment is:

Patent category	Current commercial relevance
Core chemical compound	Low after expiration
Hydrochloride salt	Low unless a specific live claim remains
Conventional tablet excipients	Low to moderate
Amorphous or crystalline form	Potentially moderate
Manufacturing process	Moderate if process is difficult to design around
Modified-release formulation	Potentially moderate
Method of use	Dependent on claim scope and labeled indication
Pediatric or administration claims	Potentially narrow but commercially useful

The most defensible formulation strategy is usually a design-around supported by independent analytical, stability, and process data.

Key Takeaways

• Erlotinib hydrochloride is a mature genericized oncology product with no biosimilar exposure.
• The main formulation challenge is pH-dependent solubility and the impact of acid-reducing agents on exposure.
• A conventional immediate-release tablet remains the strongest risk-adjusted commercial platform.
• Surfactants, superdisintegrants, particle engineering, and moisture-barrier coatings offer the most practical excipient levers.
• Amorphous dispersions and lipid systems can create differentiation but carry higher cost and regulatory risk.
• Core composition-of-matter protection is no longer the primary commercial barrier.
• Remaining patent risk is more likely to involve narrow formulation, solid-state, manufacturing, or method-of-use claims.
• Excipient suppliers should compete through dissolution consistency, process robustness, stability, and regulatory support.
• Commercial upside is greatest in generic tenders, emerging markets, and cost-sensitive oncology channels.
• A new formulation must demonstrate a measurable benefit to justify development expenditure or a price premium.

FAQs

Can lactose be used in erlotinib hydrochloride tablets?

Yes. Lactose monohydrate is used in the originator-style formulation and can function as a diluent. Compatibility, moisture, reducing-sugar interactions, and the selected manufacturing process should be evaluated.

Is sodium lauryl sulfate necessary in an erlotinib formulation?

No. It is a useful wetting agent, but alternatives can be evaluated. The decision should be based on dissolution, tolerability, tablet performance, and stability data.

Can erlotinib hydrochloride be formulated as an oral suspension?

Potentially, but the product would require control of dose uniformity, sedimentation, redispersibility, taste, chemical stability, microbial quality, and container compatibility.

Does a new erlotinib excipient combination automatically receive patent protection?

No. Patentability depends on novelty, non-obviousness, enablement, written description, and claim scope. A routine substitution of common excipients generally offers limited patent value.

Is an amorphous erlotinib dispersion commercially justified?

Usually only when it provides a demonstrable advantage over a conventional tablet, such as improved dissolution under relevant pH conditions, improved exposure, a new dosage form, or a meaningful manufacturing benefit.

References

1. Genentech USA, Inc. (2016). Tarceva (erlotinib) tablets, prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2019). Drug interaction studies: Study of erlotinib with acid-reducing agents. FDA labeling and clinical pharmacology information.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.